Supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial-Rationale and design

Yasuhiko Sakata, Kotaro Nochioka, Masanobu Miura, Tsuyoshi Takada, Soichiro Tadaki, Satoshi Miyata, Nobuyuki Shiba, Hiroaki Shimokawa

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)

Abstract

Background: Although angiotensin receptor blockers (ARBs) are now one of the first-line drug classes for the management of hypertension, recommendations for the management of chronic heart failure (CHF) are limited. The supplemental benefit of angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial investigates whether an additive treatment with an ARB, olmesartan, reduces the mortality and morbidity in hypertensive patients with stable chronic heart failure. Methods and results: The SUPPORT trial is a prospective randomized open-label blinded endpoint study. Between October 2006 and March 2010, 1147 stable CHF patients treated with evidence-based medications were successfully randomized to either olmesartan or control group. In the olmesartan group, the ARB was initiated at the dose of 5.0-10. mg, and was then increased up to 40. mg/day, when possible. No ARBs were allowed in the control group. Primary outcome measure in the SUPPORT trial is the composite of all-cause death, non-fatal acute myocardial infarction, non-fatal stroke and hospital admission due to worsening heart failure. The participants will be followed for at least 3 years until March 2013. Conclusions: The SUPPORT trial will elucidate the supplemental benefits of an ARB, olmesartan, in hypertensive patients with CHF.

Original languageEnglish
Pages (from-to)31-36
Number of pages6
JournalJournal of cardiology
Volume62
Issue number1
DOIs
Publication statusPublished - 2013 Jul
Externally publishedYes

Keywords

  • Angiotensin receptor blocker
  • Heart failure
  • Hypertension
  • Olmesartan

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial-Rationale and design'. Together they form a unique fingerprint.

Cite this